Also trades as: AGYTF (OTC) · $vol 0M
AGY.L LSE
Allergy Therapeutics plc
1W: +0.0%
1M: -9.5%
3M: -30.4%
YTD: -59.4%
1Y: -40.6%
3Y: +66.7%
5Y: -99.8%
£4.75 ($0.06)
-0.01 (-0.21%)
Weekly Expected Move ±8.3%
£4
£4
£5
£5
£6
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Cash Flow Trends
Operating Cash Flow
-$29M
+10.6% ▲
Capital Expenditures
$3M
+4.0% ▲
5Y CAGR: +5.1%
Free Cash Flow
-$32M
+10.0% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$125K
+93.5% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $3M | -$14M | -$43M | -$40M | -$39M |
| Depreciation & Amort. | $4M | $4M | $4M | $4M | $4M |
| Stock-Based Comp. | $635K | $469K | $114K | $0 | $871K |
| Change in Working Capital | $2M | -$6M | $8M | -$1M | -$3M |
| Other Non-Cash Items | $7M | $16M | $349K | $5M | $9M |
| Operating Cash Flow | $9M | -$14M | -$31M | -$32M | -$29M |
| — Investing Activities — | |||||
| Capital Expenditures | -$3M | -$3M | -$5M | -$3M | -$3M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 |
| Investment Purchases | -$194K | -$179K | -$159K | $0 | $0 |
| Investment Sales | $0 | $0 | $0 | $2M | $267K |
| Other Investing | $0 | $179K | $159K | $135K | $0 |
| Investing Cash Flow | -$3M | -$3M | -$5M | -$1M | -$3M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$132K | -$957K | $25M | $33M | $35M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$2M | -$2M | -$2M | -$2M | -$3M |
| Financing Cash Flow | -$2M | -$3M | $30M | $31M | $32M |
| Net Change in Cash | $3M | -$20M | -$6M | -$2M | -$125K |
| Cash End of Period | $40M | $21M | $15M | $13M | $13M |
| Free Cash Flow | $6M | -$17M | -$36M | -$36M | -$32M |